Antibiotic Usage & Resistance Reporting
NHSN AU/AR Module Data
0
Total DOT
Days of Therapy (2026-03)
0
DOT/1000 PD
Rate per Patient Days
13
First Isolates
Q1 2026
7
Unique Organisms
Q1 2026
Antibiotic Usage (AU) - 2026-03
No antibiotic usage data available for the current period. View detailed AU report
Antimicrobial Resistance (AR) - Q1 2026
Resistance Phenotypes
| Phenotype | Location | Eligible Isolates | Positive | % Positive |
|---|---|---|---|---|
|
VRE
Vancomycin-resistant Enterococcus |
T5A | 1 | 1 | 100.0% |
|
ESBL
Extended-spectrum beta-lactamase |
T5A | 4 | 0 | 0.0% |
|
CRE
Carbapenem-resistant Enterobacterales |
T5A | 6 | 0 | 0.0% |
|
ESBL
Extended-spectrum beta-lactamase |
T4 | 1 | 0 | 0.0% |
|
CRE
Carbapenem-resistant Enterobacterales |
T4 | 1 | 1 | 100.0% |
|
VRE
Vancomycin-resistant Enterococcus |
G6N | 1 | 0 | 0.0% |
|
CRE
Carbapenem-resistant Enterobacterales |
G6N | 3 | 1 | 33.3% |
|
CRPA
Carbapenem-resistant Pseudomonas aeruginosa |
G6N | 2 | 1 | 50.0% |
|
ESBL
Extended-spectrum beta-lactamase |
G5S | 1 | 0 | 0.0% |
|
CRE
Carbapenem-resistant Enterobacterales |
G5S | 1 | 0 | 0.0% |
|
MRSA
Methicillin-resistant Staphylococcus aureus |
T5B | 1 | 0 | 0.0% |
|
CRE
Carbapenem-resistant Enterobacterales |
T5B | 2 | 1 | 50.0% |
|
CRPA
Carbapenem-resistant Pseudomonas aeruginosa |
T5B | 1 | 1 | 100.0% |
Denominators - 2026-03
| Location | Patient Days | Central Line Days | Catheter Days | Ventilator Days |
|---|---|---|---|---|
| A6N | 13 | 0 | 0 | 0 |
| G5S | 26 | 0 | 0 | 0 |
| G6N | 39 | 0 | 0 | 0 |
| T4 | 26 | 0 | 0 | 0 |
| T5A | 65 | 0 | 0 | 0 |
| T5B | 39 | 0 | 0 | 0 |